Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Immuron achieves record Travelan® sales | ||
By: GlobeNewswire - 13 Feb 2024 | Back to overview list |
|
Highlights:
MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Australia Australian Bureau of Statistics: short term resident returns in November 2023 were 31% higher than November 2022 1. USA International Trade Administration Total U.S. citizen international visitor departures from the United States in November 2023 were 11% higher than in November 2022. 2 2. https://www.trade.gov/us-international-air-travel-statistics-i-92-data. Canada Flavio Palumbo, Chief Commercial Officer said, “We are excited by the strong sales results on Travelan®. Immuron’s investment to drive awareness of the Travelan® brand has seen strong sales results in Australia over the summer peak travel period. We hope to get similar growth of the brand as we increase our investment and distribution in North America during the spring / summer vacation peak period.” This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven Lydeamore About Immuron For more information visit: http://www.immuron.com |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |